The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

AGTR1  -  angiotensin II receptor, type 1

Canis lupus familiaris

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of AGTR1


High impact information on AGTR1


Chemical compound and disease context of AGTR1


Biological context of AGTR1


Anatomical context of AGTR1


Associations of AGTR1 with chemical compounds


Other interactions of AGTR1


Analytical, diagnostic and therapeutic context of AGTR1


  1. Diastolic properties in canine hypertensive left ventricular hypertrophy: effects of angiotensin converting enzyme inhibition and angiotensin II type-1 receptor blockade. Hayashida, W., Donckier, J., Van Mechelen, H., Charlier, A.A., Pouleur, H. Cardiovasc. Res. (1997) [Pubmed]
  2. Effects of BIBR-277, an angiotensin II type 1 receptor antagonist, on stunned myocardium in dogs. Izumi, H., Nakai, T., Kano, S., Hoshi, K., Ichihara, K. Coron. Artery Dis. (1996) [Pubmed]
  3. Effects of angiotensin II type 1 receptor antagonist (candesartan) in preventing fatal ventricular arrhythmias in dogs during acute myocardial ischemia and reperfusion. Hiura, N., Wakatsuki, T., Yamamoto, T., Nishikado, A., Oki, T., Ito, S. J. Cardiovasc. Pharmacol. (2001) [Pubmed]
  4. Angiotensin II type 1 receptor blockade prevents alcoholic cardiomyopathy. Cheng, C.P., Cheng, H.J., Cunningham, C., Shihabi, Z.K., Sane, D.C., Wannenburg, T., Little, W.C. Circulation (2006) [Pubmed]
  5. Local stress, not systemic factors, regulate gene expression of the cardiac renin-angiotensin system in vivo: a comprehensive study of all its components in the dog. Lee, Y.A., Liang, C.S., Lee, M.A., Lindpaintner, K. Proc. Natl. Acad. Sci. U.S.A. (1996) [Pubmed]
  6. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. Kumagai, K., Nakashima, H., Urata, H., Gondo, N., Arakawa, K., Saku, K. J. Am. Coll. Cardiol. (2003) [Pubmed]
  7. The effects of candesartan and ramipril on adrenal catecholamine release in anaesthetized dogs. Critchley, L., Ding, B., Fok, B., Wang, D., Tomlinson, B., James, A., Thomas, G.N., Critchley, J. Eur. J. Pharmacol. (2004) [Pubmed]
  8. Angiotensin II receptor subtypes involved in the modulation of purinergic and adrenergic vasoconstrictions to periarterial electrical nerve stimulation in the canine splenic artery. Yang, X.P., Chiba, S. J. Cardiovasc. Pharmacol. (2003) [Pubmed]
  9. Upregulation of angiotensin II type 2 receptor and limitation of myocardial stunning by angiotensin II type 1 receptor blockers during reperfused myocardial infarction in the rat. Jugdutt, B.I., Menon, V. J. Cardiovasc. Pharmacol. Ther. (2003) [Pubmed]
  10. Angiotensin II inhibition during myocardial ischemia-reperfusion in dogs: effects on leukocyte infiltration, nitric oxide synthase isoenzymes activity and left ventricular ejection fraction. de Gusmão, F.M., Becker, C., Carvalho, M.H., Barros, L.F. International journal of cardiology. (2005) [Pubmed]
  11. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 5th communication: hemodynamic effects of valsartan in dog heart failure models. Yamamoto, S., Hayashi, N., Kometani, M., Nakao, K. Arzneimittel-Forschung. (1997) [Pubmed]
  12. Effects of angiotensin converting enzyme inhibitor and angiotensin II type 1 receptor blocker on cardiac dysfunction induced by isoproterenol in dogs. Ohta, T., Hasebe, N., Tsuji, S., Jin, Y.T., Kido, S., Natori, S., Sato, M., Kikuchi, K. J. Cardiovasc. Pharmacol. (2001) [Pubmed]
  13. Angiotensin II type 1 receptor antagonist, TCV-116, prevents neointima formation in injured arteries in the dog. Miyazaki, M., Shiota, N., Sakonjo, H., Takai, S. Jpn. J. Pharmacol. (1999) [Pubmed]
  14. Cardiovascular effects of L-158,809, a new angiotensin type 1 receptor antagonist, assessed using the halothane-anesthetized in vivo canine model. Yoneyama, M., Sugiyama, A., Yoshida, H., Satoh, Y., Hashimoto, K. Jpn. J. Pharmacol. (2002) [Pubmed]
  15. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 3rd communication: hemodynamic effects of valsartan in rats and dogs. Hayashi, N., Yamamoto, S., Kometani, M., Nakao, K. Arzneimittel-Forschung. (1997) [Pubmed]
  16. Efficacy of pretreatment with the angiotensin II type 1 receptor blocker UP269-6 and losartan in the dog: effect on hemodynamics and ischemia-reperfusion. O'Brien, D.W., Xu, Y., Menon, V., Jugdutt, B.I. J. Cardiovasc. Pharmacol. Ther. (2000) [Pubmed]
  17. Angiotensin II type 1 receptor antagonist versus angiotensin I-converting enzyme inhibitor in experimental renal diseases. Jover, B., Demeilliers, B. Fundamental & clinical pharmacology. (2000) [Pubmed]
  18. Unequal effects of renin-angiotensin system inhibitors in acute cardiac dysfunction induced by isoproterenol. Ohta, T., Hasebe, N., Tsuji, S., Izawa, K., Jin, Y.T., Kido, S., Natori, S., Sato, M., Kikuchi, K. Am. J. Physiol. Heart Circ. Physiol. (2004) [Pubmed]
  19. Molecular cloning and pharmacological characterization of an atypical gerbil angiotensin II type-1 receptor and its mRNA expression in brain and peripheral tissues. Moriuchi, R., Shibata, S., Himeno, A., Jöhren, O., Hoe, K.L., Saavedra, J.M. Brain Res. Mol. Brain Res. (1998) [Pubmed]
WikiGenes - Universities